Chapter 94
Approach to Massive Transfusion in the ICU

94.1 Introduction

Massive transfusion (MT) is a critical intervention in the management of severe hemorrhage, frequently encountered in trauma, perioperative, obstetric emergencies, and other critical care settings. It involves rapidly replacing blood products to restore circulating volume, oxygen-carrying capacity, and hemostasis. Early and structured intervention is crucial, as uncontrolled bleeding can lead to the "triad of death": hypothermia, acidosis, and coagulopathy [1, 2] [Ref: Algorithm 94.1].

94.2 Historical Perspective and Evolution

The development of massive transfusion protocols (MTPs) has its roots in military medicine during World Wars I and II. The high incidence of traumatic injuries and hemorrhage on the battlefield necessitated efficient blood replacement strategies. These military practices emphasized rapid, coordinated transfusion efforts to save lives under extreme conditions. Over time, the principles derived from these experiences transitioned into civilian medicine, establishing standardized MTPs in hospitals worldwide. The evolution reflects a growing understanding of the importance of timely and balanced transfusion therapy in managing massive hemorrhage [3].

94.3 Definitions of Massive Transfusion

Various definitions of massive transfusion exist, reflecting the dynamic and urgent nature of severe bleeding. Traditional definitions include:

S. B. Mishra et al., *Mastering ICU Care*,
https://doi.org/10.1007/978-981-95-0179-3_94

- Replace more than 10 units of packed red blood cells (PRBCs) within 24 h.
- Loss of one blood volume within 24 h.

Dynamic definitions, which better capture clinical urgency, include:

- Replacement of 50% of total blood volume within 3 h.
- Transfusion of more than 4 units of PRBCs in 1 h with ongoing bleeding.

Understanding these definitions aids in the early recognition and timely activation of MTPs.

94.4 Predictive Tools

Early identification of patients likely to require massive transfusion improves outcomes. Predictive tools include:

- Assessment of Blood Consumption (ABC) Score: Considers factors like penetrating injury, systolic blood pressure <90 mmHg, heart rate >120 bpm, and a positive Focused Assessment with Sonography for Trauma (FAST) exam.
- Shock Index: Calculated as heart rate divided by systolic blood pressure; values >0.9 indicate significant hypovolemia [4].

These tools assist clinicians in making prompt decisions regarding MTP activation.

94.5 Institutional Protocols

Institutional MTPs facilitate effective communication among multidisciplinary teams, ensure the rapid availability of blood products, and standardize care. Key components include:

- Clear activation criteria and procedures.
- Defined roles and responsibilities for team members.
- Guidelines for blood product ratios and adjunctive therapies.

Standardized protocols minimize delays and reduce variability in patient care during emergencies.

94.6 Clinical Contexts

Massive transfusion may be required in various clinical scenarios:

- Trauma: Severe injuries, especially penetrating trauma, can lead to life-threatening hemorrhage.
- Obstetric Hemorrhage: Conditions like placenta previa, uterine atony, or ruptured ectopic pregnancy necessitate rapid intervention.
- Gastrointestinal Bleeding: Massive bleeding from varices or ulcers requires prompt management.
- Perioperative Crises: Surgical complications may result in unexpected significant blood loss.

Each scenario demands specific considerations regarding patient management and transfusion strategies.

94.7 Immediate Assessment of Blood Product Availability

Upon recognizing significant hemorrhage:

- If blood products are available: Initiate transfusion using a balanced ratio (commonly 1:1:1) of PRBCs, plasma, and platelets to mimic whole blood and reduce coagulopathy risk.
- If not immediately available: Begin resuscitation with crystalloids while urgently arranging for blood products.

Timely transfusion is crucial to address hypovolemia and coagulopathy effectively.

94.8 Evaluation of Coagulation Parameters

Assess coagulation status using:

- Laboratory Tests: Prothrombin time (PT)/International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen levels, platelet counts.
- Thromboelastography (TEG) or Rotational Thromboelastometry (ROTEM): Provide real-time insights into clot formation, strength, and stability.

Abnormal parameters indicate the need for targeted therapy with plasma, platelets, cryoprecipitate, or fibrinogen concentrate.

94.9 Laboratory and Real-Time Monitoring

Continuous monitoring guides ongoing management:

- Hemoglobin and Hematocrit: Evaluate oxygen-carrying capacity.
- Lactate Levels: Reflect tissue perfusion and oxygenation.
- Electrolytes: Monitor calcium and potassium levels to detect hypocalcemia or hyperkalemia.
- TEG/ROTEM: Adjust transfusion therapy based on dynamic coagulation profiles.

Regular assessment ensures appropriate and effective intervention [5].

94.10 Adjunctive Therapies

Adjunctive measures enhance hemostasis:

- Tranexamic Acid (TXA): Early administration reduces mortality in trauma by inhibiting fibrinolysis.
- Calcium Supplementation: Corrects hypocalcemia due to citrate binding from transfused blood products, essential for coagulation and cardiac function.

The Joint Trauma System Clinical Practice Guideline (CPG) for Damage Control Resuscitation suggests that 1 g of calcium chloride or 3 g of calcium gluconate be administered to patients in hemorrhagic shock during or immediately after the first unit of blood product transfusion and then with ongoing resuscitation after every 4 units of blood products, with monitoring of iCa and repletion if <1.2 mmol/L

- Fibrinogen Concentrate or Cryoprecipitate: Addresses low fibrinogen levels critical for clot formation.

Four-factor prothrombin complex concentrate (4F-PCC): It is a pathogen-reduced, freeze-dried product that provides therapeutic levels of vitamin K-dependent clotting factors: factors II, VII, IX, and X. It has been suggested as a possible adjunct treatment to counteract the effects of trauma-induced coagulopathy (TIC). While 4F-PCC is commonly used to reverse anticoagulation caused by vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) in cases of severe bleeding, it has also been employed in patients with TIC who are not on anticoagulants. Its advantages include quick correction of coagulopathy, the need for smaller infusion volumes, and reduced risks associated with transfusions. Due to these benefits, European guidelines recommend 4F-PCC as part of the management strategy for bleeding and coagulopathy after major trauma.

Evidence supports the early use of these therapies to improve patient outcomes.

94.11 Prevention of the Triad of Death

Preventing hypothermia, acidosis, and coagulopathy is vital:

- Hypothermia: Use warming devices and warmed fluids to maintain body temperature above 36 °C.
- Acidosis: Optimize ventilation and perfusion; consider bicarbonate therapy if necessary.
- Coagulopathy: Administer appropriate blood products guided by coagulation monitoring.

Addressing these factors reduces bleeding and improves survival.

94.12 Control of Bleeding Source

Definitive bleeding control is essential:

- Surgical Intervention: Expedient surgery may be necessary to control internal bleeding.
- Interventional Radiology: Techniques like embolization can manage bleeding in less accessible areas.
- Endoscopic Procedures: Useful in gastrointestinal bleeding for direct hemostasis.

Persistent hemorrhage requires a coordinated, multidisciplinary approach.

94.13 Complications of Massive Transfusion

Potential complications include:

- Citrate Toxicity and Hypocalcemia: Result from large volumes of citrate-preserved blood; monitor calcium levels and administer calcium gluconate or chloride as needed.
- Hyperkalemia: Due to potassium leakage from stored red blood cells; monitor serum potassium and manage accordingly.
- Immunological Reactions: Such as transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO); recognize early signs and provide supportive care.
- Dilutional Coagulopathy: Caused by transfusion of PRBCs without adequate plasma or platelets; prevented by balanced transfusion ratios.

Awareness and prompt management of these complications are crucial.

94.14 Special Populations

94.14.1 Pediatric Patients

- Considerations: Smaller blood volumes necessitate precise dosing; higher risk of volume overload and hypothermia.
- Transfusion Strategies: Use weight-based calculations; utilize warmed blood products.

94.14.2 Obstetric Patients

- Considerations: Unique physiological changes in pregnancy affect hemodynamics and coagulation.
- Transfusion Strategies: Rapid volume replacement; consider uterotonic agents and coordination with obstetric specialists.

Tailoring transfusion strategies to these populations improves safety and efficacy.

94.15 Quality Improvement and Metrics

Implementing quality measures enhances MTP effectiveness:

- Performance Metrics: Track activation times, adherence to protocols, patient outcomes.
- Regular Audits: Identify deviations and areas for improvement.
- Education and Training: Ongoing staff education ensures familiarity with MTPs.

Continuous evaluation promotes optimal patient care and resource utilization.

94.16 Future Directions

Emerging advancements include:

- Use of Whole Blood: Reintroducing whole blood transfusions in civilian settings may simplify logistics and improve outcomes.
- Artificial Blood Products: Development of synthetic oxygen carriers and hemoglobin-based substitutes offers potential alternatives.
- Enhanced Monitoring Technologies: Point-of-care devices for real-time assessment may refine transfusion strategies.

Staying informed about these developments is essential for evolving practice.

94.17 Conclusion

Management of massive transfusion in the ICU requires early recognition, rapid MTP activation, and a coordinated multidisciplinary approach. Utilizing predictive tools, adhering to institutional protocols, and customizing strategies for specific clinical contexts enhance patient outcomes. Continuous monitoring, adjunctive therapies, and prevention of complications are integral to effective care. Special considerations for pediatric and obstetric populations, along with commitment to quality improvement, further optimize management. As advancements continue, integrating new technologies and practices will improve survival rates for patients requiring massive transfusion.

Algorithm 94.1: Approach to massive transfusion in the ICU



Bibliography

1. Moore SA, Raval JS. Massive transfusion: a review. Ann Blood. 2022;7:18.
2. Lin VS, Sun E, Yau S, Abeyakoon C, Seamer G, Bhopal S, et al. Definitions of massive transfusion in adults with critical bleeding: a systematic review. Crit Care. 2023;27(1):265.
3. Young PP, Cotton BA, Goodnough LT. Massive transfusion protocols for patients with substantial hemorrhage. Transfus Med Rev. 2011;25(4):293–303.
4. Patil V, Shetmahajan M. Massive transfusion and massive transfusion protocol. Indian J Anaesth. 2014;58(5):590–5.
5. Pham HP, Shaz BH. Update on massive transfusion. Br J Anaesth. 2013;111(Suppl 1):i71–82.